@RaceOncology
Hi Dr T. We've found that Zantrene is synergistic with Cafilzomib in a cell line H929. Is the synergy presumably due to FTO? And if this is the case, would a coformulation of Zan+Car as a synergistic drug mainly be relevant in Myeloma lines that are FTO sensitive?
Would this require a companion diagnostic for FTO level determination as well? Or would it be used mainly for cardioprotection and the synergy may/may not be important if a CDx isn't used?
I'm just trying to determine how a trial would be set up and what the end point would be for it.
@RaceOncologyHi Dr T. We've found that Zantrene is synergistic...
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |